Articles

Cost-effectiveness of Growth Hormone and its Consumption Indications: A Systematic Review of Economic Evaluation Studies

Abstract

Context: Growth hormone deficiency (GHD) is one of the most important reasons of short stature in children, which can be treated by early diagnosis. Stature is a good measure for assessing a child's overall growth and health, and height can affect one's psychosocial and social well-being. Human Growth Hormone (HGH) has extensive effects on biological processes, and helps to influence height. Due to the high cost of growth hormone GH drugs, in most countries it is prescribed according to scientific indications.
Methods: The present study is a systematic review. From the beginning of 2002 to February 2019, by searching Web of Science, PubMed, Scopus, SID, Embase and Magiran databases, related studies in the scope of health technology assessment and Economic evaluation were reviewed. Finally, 11 related studies were entered the study.
Results: The use of GH therapy was effective in increasing the patients' life quality. The growth of children treated with GH was more than 2.5 cm per year more than untreated children. Furthermore, the results of the studies indicated the cost-effectiveness of using GH. So that the cost of each centimeter increase in height is on average US $ 20,000, and the incremental cost-effectiveness based on QALY's criteria in studies for various indications (Turner syndrome, idiopathic short stature, growth hormone deficiency, Prader Willi syndrome , Infants small for gestational age (SGA), chronic renal failure (CRF) and (SHOX-D) is different. The highest cost efficacy per kali is for growth hormone deficiency (from £ 20,000 to £ 30,000) and the lowest cost efficacy is for Prader Willi (from £ 55,000 to £ 135,000).
Conclusions: Studies showed that GH increases the height of the children treated with GHD, compared to the control children; hence, the use of growth hormone is recommended after doing the experiments for all children with GHD. This issue can be considered by health policy makers to implement in healthcare programs.

1. Assar SSH, Riahi K, Kheradmand K. Frequency of growth hor mone deficiency in short stature children. J Isfahan Med Sch. 2010;28:104.
2. Germanyuk T, Kryvoviaz O, Toziuk O, Balicka O, Ivko T, Polysh chuk Y, et al. Dwarfism: Accessibility of somatropin therapy for patients with growth hormone deficiency and impact of its cost on the state budget in Ukraine. Asia J Pharm. 2017;11(4):794-7.
3. Maeda E, Higashi T, Hasegawa T, Yokoya S, Mochizuki T, Ishii T, et al. Effects of financial support on treatment of adolescents with growth hormone deficiency: A retrospective study in Japan. BMC Health Serv Res. 2016;16(1):602.
4. Howard SR, Butler GE. An analysis of the clinical and cost effec tiveness of growth hormone replacement therapy before and during puberty: Should we increase the dose? Horm Res Paedi atr. 2013;79(2):75-82.
5. Saz-Parkinson Z, Granados Alonso MDS, Amate JM. Study of ad herence to recombinant growth hormone treatment of children with a GH deficiency: Contributions to treatment control and economic impact. Madrid: Instituto de Salud Carlos III; 2013.
6. Christensen T, Buckland A, Bentley A, Djurhuus C, Baker-Searle R. Cost-effectiveness of somatropin for the treatment of short chil dren born small for gestational age. Clin Ther. 2010;32(6):1068-82.
7. Valentim J, Passos V, Mataveli F, Calabro A. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromeg aly in Brazil. Arq Bras Endocrinol Metabol. 2008;52(9):1452-60.
8. Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K, et al. Clinical effectiveness and cost-effectiveness of growth hor mone in children: A systematic review and economic evaluation. Health Technol Assess. 2002;6(18):1-168.
9. Yokoya S, Tanaka T, Itabashi K, Osada H, Hirai H, Seino Y. Efficacy and safety of growth hormone treatment in Japanese children with small-for-gestational-age short stature in accordance with Japanese guidelines. Clin Pediatr Endocrinol. 2018;27(4):225-34.
10. Takeda A, Cooper K, Bird A, Baxter L, Frampton GK, Gospodarevskaya E, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess. 2010;14(42):1-209, iii-iv.
11. Bolin K, Jonsson B, Koltowska-Haggstrom M, Prutz C, Sandin R, editors. The cost-effectiveness of growth hormone (GH) treat ment (Genotropin [reg]) in adult patients with growth hormone deficiency (GHD). 11th European Congress of Endocrinology; 2009; Turkey BioScientifica.
12. Joshi AV, Munro V, Russell MW. Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in chil dren. Curr Med Res Opin. 2006;22(2):351-7.
13. Wijnen B, Van Mastrigt G, Redekop WK, Majoie H, De Kinderen R, Evers S. How to prepare a systematic review of economic evalu ations for informing evidence-based healthcare decisions: Data extraction, risk of bias, and transferability (part 3/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):723-32.
14. Vitova V, Tichopad A. Cost-effectiveness of somatropin adminis tration with increased adherence due to monitoring compared to non-monitored administration in patients with growth hor mone deficiency. Value Health. 2013;16(7):A622-3.
15. Twena N, Christensen T, Buckland A, Bentley A, Djurhuus CB. P-40 Economic evaluation of somatropin (Norditropin®) for the treat ment of short children born SGA in Sweden. Growth Horm IGF Res. 2008;18:S39.
16. Christensen T, Buckland AG, Bentley A, Djuurhus C, Wing C. Pdb19 economic evaluation of somatropin (norditropin) for the treatment of short children born small for gestational age (Sga). Value in Health. 2008;11(3):A223.
17. Christensen T, Fidler C, Bentley A, Djurhuus C. The cost-effective ness of somatropin treatment for short children born small for gestational age (SGA) and children with growth hormone defi ciency (GHD) in Sweden. J Med Econ. 2010;13(1):168-78.
18. Tasavon Gholamhoseini M, Barouni M, Afsharzadeh N, Jafari Si rizi M. Cost-effectiveness of growth hormone (somatropin) for the treatment of children with short stature. J Payavard Salamat. 2018;12(4):286-95.
19. Craig D, Fayter D, Stirk L, Crott R. Growth monitoring for short stature: update of a systematic review and economic model. Health Technol Assess. 2011;15(11):iii-iv, 1-64.
20. National Institute for Health and Clinical Excellenc. Human growth hormone in children (review of NICE technology ap praisal guidance 42). National Institute for Health and Clinical Excellence; 2009.
Files
IssueVol 3, No 1 (2019) QRcode
SectionArticles
DOI https://doi.org/10.18502/htaa.v3i1.5848
Keywords
Children's Stature Cost- Effectiveness Growth Hormone Growth Hormone Deficiency Treatment Incremental Cost-effectiveness Life Quality
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Pakdaman M, Golmakani F, Dehghan HR, Valagohr R, Beik Yazdi A, Namayande M. Cost-effectiveness of Growth Hormone and its Consumption Indications: A Systematic Review of Economic Evaluation Studies. Health Tech Ass Act. 2020;3(1).